Skip to main navigation Skip to search Skip to main content

Prolonged survival after treatment of diffuse intrinsic pontine glioma with radiation, temozolamide, and bevacizumab: Report of 2 cases

  • Dolly G. Aguilera
  • , Claire Mazewski
  • , Laura Hayes
  • , Cathy Jordan
  • , Natia Esiashivilli
  • , Anna Janns
  • , Tobey J. MacDonald
  • Emory University
  • Children's Healthcare of Atlanta

Research output: Contribution to journalArticlepeer-review

18 Scopus citations

Abstract

BACKGROUND: Diffuse intrinsic pontine gliomas have poor prognosis. OBSERVATION: We report on 2 patients with diffuse intrinsic pontine glioma treated with radiation, followed by temozolamide 200 mg/m/d for 5 days every 28 days and bevacizumab 10 mg/kg/dose every 14 days. Both patients have ongoing PFS of 37 and 47 months from diagnosis. A decrease in tumor size by >65% was observed in both the patients. Both patients continue treatment. No steroid requirement since 10 weeks after radiation. Quality of life is excellent and the chemotherapy regimen is well tolerated. CONCLUSIONS: A clinical trial in an expanded cohort is warranted to determine the toxicity and evaluate response.

Original languageEnglish
Pages (from-to)e42-e46
JournalJournal of Pediatric Hematology/Oncology
Volume35
Issue number1
DOIs
StatePublished - Jan 2013
Externally publishedYes

Fingerprint

Dive into the research topics of 'Prolonged survival after treatment of diffuse intrinsic pontine glioma with radiation, temozolamide, and bevacizumab: Report of 2 cases'. Together they form a unique fingerprint.

Cite this